General Practitioners' Awareness and Perception of Current Pneumococcal Vaccination for Adult Patients with Known Risk Factors in Switzerland: Evidence from a Survey.

Sandro Tiziano Stoffel, Matthias Schwenkglenks, Thomas Mutschler
Author Information
  1. Sandro Tiziano Stoffel: Research Department of Behavioural Science and Health, UCL, London WC1E 6BT, UK. ORCID
  2. Matthias Schwenkglenks: Institute of Pharmaceutical Medicine (ECPM), University of Basel, CH-4056 Basel, Switzerland. ORCID
  3. Thomas Mutschler: Medical Affairs, MSD, CH-6005 Lucerne, Switzerland.

Abstract

In Switzerland, the National Immunization Advisory Group (NITAG) has formulated recommendations for pneumococcal vaccination among adult risk patients. Little is known about general practitioners' (GPs') perception, knowledge, and implementation of these recommendations. Therefore, we investigated GPs' awareness and drivers of and barriers to pneumococcal vaccination using a cross-sectional web-based survey of GPs. Of the 300 study participants, 81.3% were aware of the recommendations for vaccinating at-risk adult patients, but only 42.7% were aware of all risk groups. The recommendations were perceived by 79.7% as slightly to very complex. Most GPs (66.7%) had good arguments to convince patients to get vaccinated, but only 41.7% reported recognizing patients at risk for pneumococcal disease, and only 46.7% checked their patients' vaccination status and proposed vaccination if needed. The main reasons for not vaccinating were patients' refusal (80.1%), lack of reimbursement by the health insurance (34.5%), patients' fear of side effects (25.1%), and lack of regulatory approval despite the NITAG recommendations (23.7%). Most (77.3%) agreed that the treating chronic disease specialist should recommend the vaccination and 94.7% believed that adult-risk patients would not be aware of their need for pneumococcal vaccinations. Optimal implementation of the recommendations will require addressing knowledge gaps and reported barriers.

Keywords

References

  1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):845-57 [PMID: 23703506]
  2. Respirology. 2009 Mar;14(2):167-79 [PMID: 19272081]
  3. PLoS One. 2013 Nov 05;8(11):e78210 [PMID: 24223775]
  4. Vaccine. 2022 Oct 12;40(43):6206-6210 [PMID: 36175212]
  5. Vaccine. 2002 Jan 31;20(9-10):1383-92 [PMID: 11818157]
  6. Vaccine. 2023 Jan 4;41(1):263-273 [PMID: 36456389]
  7. Scand J Rheumatol. 2017 Nov;46(6):446-453 [PMID: 28145151]
  8. PLoS One. 2022 Mar 22;17(3):e0265433 [PMID: 35316288]
  9. Curr Opin Infect Dis. 2016 Apr;29(2):187-96 [PMID: 26779776]
  10. Pediatr Infect Dis J. 2006 Jun;25(6):494-501 [PMID: 16732146]
  11. PLoS One. 2019 Aug 8;14(8):e0220848 [PMID: 31393931]
  12. Lancet Glob Health. 2019 Jan;7(1):e58-e67 [PMID: 30554762]
  13. Am J Gastroenterol. 2019 Jul;114(7):1130-1141 [PMID: 31205131]
  14. Hum Vaccin Immunother. 2021 Jan 2;17(1):162-169 [PMID: 32429734]
  15. J Am Board Fam Med. 2018 Jan-Feb;31(1):94-104 [PMID: 29330244]
  16. Eur J Intern Med. 2019 Nov;69:25-31 [PMID: 31445784]
  17. BMC Infect Dis. 2021 Jan 6;21(1):12 [PMID: 33407202]
  18. PLoS One. 2018 Dec 7;13(12):e0208601 [PMID: 30532274]
  19. Dig Liver Dis. 2018 Jun;50(6):563-567 [PMID: 29371056]
  20. Vaccine. 2022 Aug 5;40(33):4911-4921 [PMID: 35811205]
  21. Vaccine. 2015 Mar 17;33(12):1446-52 [PMID: 25659279]
  22. JAMA. 2006 Sep 6;296(9):1094-102 [PMID: 16954489]
  23. PLoS One. 2016 Apr 20;11(4):e0153848 [PMID: 27096429]
  24. BMC Fam Pract. 2016 Jul 29;17:98 [PMID: 27473612]
  25. Fam Pract. 2011 Dec;28(6):632-7 [PMID: 21746697]
  26. Adv Ther. 2013 Apr;30(4):387-405 [PMID: 23605248]
  27. Hum Vaccin Immunother. 2020 Nov 1;16(11):2809-2815 [PMID: 32238041]
  28. Int J Gen Med. 2012;5:967-74 [PMID: 23204861]
  29. BMJ Open. 2019 Apr 11;9(4):e025737 [PMID: 30975679]
  30. Front Public Health. 2022 Jan 31;9:759602 [PMID: 35174130]
  31. BMC Geriatr. 2023 Jan 2;23(1):2 [PMID: 36593474]

Grants

  1. not applicable/MSD (Switzerland)

Word Cloud

Created with Highcharts 10.0.07%recommendationspneumococcalvaccinationpatientsriskknowledgeawarediseasepatients'NITAGadultgeneralGPs'implementationbarrierssurveyGPs3%vaccinatingreported1%lackSwitzerlandNationalImmunizationAdvisoryGroupformulatedamongLittleknownpractitioners'perceptionThereforeinvestigatedawarenessdriversusingcross-sectionalweb-based300studyparticipants81at-risk42groupsperceived79slightlycomplex66goodargumentsconvincegetvaccinated41recognizing46checkedstatusproposedneededmainreasonsrefusal80reimbursementhealthinsurance345%fearsideeffects25regulatoryapprovaldespite2377agreedtreatingchronicspecialistrecommend94believedadult-riskneedvaccinationsOptimalwillrequireaddressinggapsGeneralPractitioners'AwarenessPerceptionCurrentPneumococcalVaccinationAdultPatientsKnownRiskFactorsSwitzerland:EvidenceSurveyattitudespractitionerinvasivephysicianvaccine

Similar Articles

Cited By (1)